Comparative Pharmacology
Head-to-head clinical analysis: AFREZZA versus OSENI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFREZZA versus OSENI.
AFREZZA vs OSENI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhaled human insulin that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin binds to the insulin receptor, activating tyrosine kinase activity leading to downstream metabolic effects.
OSENI is a combination of alogliptin (DPP-4 inhibitor) and pioglitazone (PPARγ agonist). Alogliptin increases incretin levels, enhancing glucose-dependent insulin secretion and suppressing glucagon. Pioglitazone improves insulin sensitivity in adipose tissue, liver, and muscle.
Inhaled powder; initial dose: 4 units per inhalation at each meal, titrated based on blood glucose; maximum 48 units per meal. Administer via Afrezza Inhaler.
1 tablet orally once daily. Each tablet contains alogliptin 12.5 mg and pioglitazone 15 mg, 25 mg, or 30 mg. Maximum daily dose: alogliptin 25 mg/pioglitazone 45 mg.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours for insulin component; clinical context: duration of glucose-lowering effect may extend beyond due to receptor binding.
Alogliptin: 12.4-21.4 hours; pioglitazone: 3-7 hours; clinical context: allows once-daily dosing.
Renal: approximately 60-80% as unchanged drug and metabolites (insulin degradation products). Biliary/fecal: minor, <20%.
Oseni (alogliptin and pioglitazone): Alogliptin: 60-71% renally excreted unchanged; pioglitazone: 15-30% renally, 60% biliary/fecal.
Category C
Category C
Antidiabetic Agent
Antidiabetic Agent